Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.06
+0.19 (3.90%)
Aug 27, 2026, 9:18 AM EDT - Market open
Coya Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 43.18 | 46.82 | 38.34 | 32.63 | 5.93 | 4.34 |
Cash & Short-Term Investments | 43.18 | 46.82 | 38.34 | 32.63 | 5.93 | 4.34 |
Cash Growth | 45.11% | 22.13% | 17.51% | 449.85% | 36.72% | -50.23% |
Other Receivables | - | - | 0.73 | 7.5 | - | - |
Receivables | - | - | 0.73 | 7.5 | - | - |
Prepaid Expenses | 3.88 | 3.12 | 5.24 | 1.07 | 1.25 | 0.24 |
Total Current Assets | 47.06 | 49.94 | 44.31 | 41.2 | 7.18 | 4.58 |
Property, Plant & Equipment | 0.01 | 0.01 | 0.04 | 0.07 | 0.09 | 0.12 |
Long-Term Deferred Charges | - | - | - | - | 1.12 | 0.09 |
Total Assets | 47.31 | 49.95 | 44.35 | 41.26 | 8.4 | 4.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.09 | 1.06 | 1.59 | 1.16 | 1.82 | 0.86 |
Accrued Expenses | 1.19 | 3.61 | 1.39 | 2.25 | 2.01 | 0.29 |
Current Income Taxes Payable | - | - | - | 0.72 | - | - |
Current Unearned Revenue | 1.23 | 1.2 | 0.85 | 0.92 | - | - |
Total Current Liabilities | 3.51 | 5.87 | 3.82 | 5.05 | 3.82 | 1.15 |
Long-Term Debt | - | - | - | - | 12.97 | - |
Long-Term Unearned Revenue | 0.52 | 1.05 | 0.95 | 0.57 | - | - |
Total Liabilities | 4.03 | 6.92 | 4.77 | 5.63 | 16.79 | 1.15 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 119.08 | 104.99 | 80.31 | 61.5 | 0.68 | 0.47 |
Retained Earnings | -75.81 | -61.96 | -40.74 | -25.86 | -17.87 | -5.62 |
Comprehensive Income & Other | - | - | - | -0.01 | - | - |
Total Common Equity | 43.28 | 43.03 | 39.58 | 35.64 | -17.19 | -5.15 |
Shareholders' Equity | 43.28 | 43.03 | 39.58 | 35.64 | -8.39 | 3.64 |
Total Liabilities & Equity | 47.31 | 49.95 | 44.35 | 41.26 | 8.4 | 4.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | 12.97 | - |
Net Cash (Debt) | 43.18 | 46.82 | 38.34 | 32.63 | -7.03 | 4.34 |
Net Cash Growth | 45.11% | 22.13% | 17.51% | - | - | -50.23% |
Net Cash Per Share | 2.17 | 2.80 | 2.52 | 3.21 | -2.71 | 1.68 |
Filing Date Shares Outstanding | 23.46 | 23.46 | 16.72 | 14.54 | 9.95 | 2.59 |
Total Common Shares Outstanding | 23.46 | 20.93 | 16.71 | 14.41 | 2.59 | 2.59 |
Working Capital | 43.55 | 44.07 | 40.48 | 36.14 | 3.36 | 3.44 |
Book Value Per Share | 1.84 | 2.06 | 2.37 | 2.47 | -6.64 | -1.99 |
Tangible Book Value | 43.28 | 43.03 | 39.58 | 35.64 | -17.19 | -5.15 |
Tangible Book Value Per Share | 1.84 | 2.06 | 2.37 | 2.47 | -6.64 | -1.99 |
Machinery | - | - | - | 0.14 | 0.14 | 0.14 |